Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza Partners AZ And Merck & Co Target US Breast Cancer Market

Executive Summary

AstraZeneca and Merck & Co's strategic collaboration on the development of olaparib and other anticancers has the US breast cancer sector in its sights, with approval of a US sNDA in the indication expected in early 2018.

Advertisement

Related Content

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
PARP Inhibitors: Rich Prospects And More Deals In Store?
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel